retatrutide phase 2 trial results NEJM Trial: 48-Week Weight Loss Explained – Bolt Pharmacy New Retatrutide Phase 3 Trial

Phase 3 TRIUMPH trials showed up to 26% body weight reduction

The Phase 3 trial program tested 4 mg, 9 mg, and 12 mg subcutaneous once-weekly doses in human participants [1][2]

No, Jardiance is an oral medication, typically taken as a once-daily pill

Differentiation amongst these agents is important, and there are several factors that will make assets from smaller companies attractive: 1) oral and infrequent dosing regimens, 2) ability to improve cardiometabolic outcomes along with weight loss, and 3) reduced GI side effects

The peptides for weight loss overview emphasizes this point across all GLP-1 class compounds

"A Small Molecule Ligand of the Glucagon-like Peptide 1 Receptor Targets Its Amino-terminal Hormone Binding Domain"